AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panel's Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.
Posted on: Tuesday, 8 July 2008, 12:01 CDT
SAN MATEO, Calif., July 8 /PRNewswire/ -- After meeting on July 1st and 2nd an FDA advisory panel recommended that all new diabetes drugs should undergo trials to rule out cardiovascular risk. 85% of US cardiologists and 65% of US endocrinologists agree with this recommendation, according to AlphaDetail Inc., a leader in cardiovascular and metabolic primary market research and key opinion leader mapping solutions to the Global Life Sciences Industry.
On July 3rd AlphaDetail launched its latest AlphaPulse(TM) survey to measure immediate physician awareness and reactions to the panel recommendation. In a brief on-line survey of 52 cardiologists and 51 endocrinologists AlphaDetail found:
-- Unaided, about 40% of physicians mentioned CV risk associated with diabetes medications as the most important development in diabetes treatment from the past month. -- When prompted, half of physicians indicated they had heard about the FDA panel recommendation to require cardiovascular safety trials for new diabetes medications -- only a day after the news was announced. -- Although most physicians from both specialties support the recommendation, twice as many cardiologists (33%) vs. endocrinologists (16%) agree strongly with it. -- However, 22% of endocrinologists disagree with the recommendation primarily because they believe it would stifle innovation and delay the availability of important new therapies. -- Physicians disagree on the most appropriate implementation of the FDA panel recommendation -- two CV safety trials vs. only one trial. -- However, more physicians believe that the two trial implementation is the most appropriate. -- Even so, a segment of physicians (25% of cardiologists and 37% of endocrinologists) would support prescribing a new diabetes therapy that is highly efficacious but has CV risk to patients that have no CV risk factors other than diabetes. -- Physicians have to make a trade-off between controlling diabetes and preventing other diabetes complications vs. preventing CV risk.
To learn more about this study, please contact Bob Latshaw at Bob.Latshaw@alphadetail.com or (215) 259-5601.
About AlphaDetail, Inc.:
At AlphaDetail, we have an unparalleled commitment to our clients. We are a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community. AlphaDetail is built on one of the industry's strongest foundations that includes a large team of exceptional analytical specialists, the industry's leading technology platform and a flexible approach to research that helps us answer our client's most challenging questions.
AlphaDetail, Inc.
CONTACT: Bob Latshaw, Vice President of Sales of AlphaDetail, Inc.,+1-215-259-5601, Bob.Latshaw@alphadetail.com
Web site: http://www.alphadetail.com/
Source: PRNewswire
Related Articles
- Diabetes doubles Alzheimer's risk
- Diabetes Significantly Increases Risk for Alzheimer's Disease and Other Dementia
- Diabetes Experts Recommend One-Two Punch for Treating Patients With Pre-Diabetes
- Gestational Diabetes Increases Cancer Risk
- Diabetes linked with risk of sudden cardiac death
- Older Americans with New-onset Diabetes Have High Risk of Pancreatic Cancer
- Diabetes and Cardiovascular Risk Markers
- Diabetes and the Risk of Lung Cancer
- Ultra-Low-Fat Menu Appears to Help Diabetics With Heart Risk
- Painkillers Should All Stay on Market, Despite Heart Risks: FDA Panel
 |
 |
User Comments (0)
RSS Feeds